ArticleBMC pregnancy and childbirth2025
Mesenchymal stem cells therapy for immune thrombocytopenia in pregnancy: a case report.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innovative strategies for immune thrombocytopenia treatment: immunomodulatory mechanisms and clinical potential of mesenchymal stem cells.Stem cell research & therapy · 2026Review
- Ningxue Shengban decoction containing serum alleviates immune thrombocytopenia by modulating CD4Stem cell research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune thrombocytopenia (ITP) during pregnancy poses unique therapeutic challenges due to the risk of maternal hemorrhage, fetal thrombocytopenia, and the safety limitations of standard treatments such as corticosteroids and intravenous immunoglobulin (IVIG). Mesenchymal stem cells (MSCs), particularly those derived from umbilical cord tissue (UC-MSCs), have shown immunomodulatory and hematopoietic supportive properties in refractory ITP, but their use during pregnancy has not been previously reported. CASE PRESENTATION: We report the case of a 41-year-old woman with a 10-year history of ITP who conceived with a baseline platelet count of 54 × 10⁹/L at 8 weeks of gestation. During pregnancy, she self-initiated UC-MSCs infusions outside guideline-directed care (five courses, 60 × 10⁶ cells/day for three consecutive days per course), followed by two postpartum courses. Platelet counts during pregnancy were maintained between 41-94 × 10⁹/L and rose to 154 × 10⁹/L postpartum. No infusion-related adverse events were observed. The pregnancy was uneventful, with no maternal hemorrhage or fetal growth restriction, and both mother and neonate had favorable outcomes.
conclusionsThis report documents the first maternal-fetal outcomes following non-standard UC-MSCs exposure in pregnancy complicated by ITP. While not medically indicated, this case highlights the reality of patient-driven use of experimental therapies and underscores the urgent need for systematic studies to evaluate maternal-fetal safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.